Applied BioCode (6598) reported revenue of NT$35.8 million for Oct 2026, +8.7% year on year and -53.7% from the previous month. Revenue for Jan–Oct 2026 was NT$648 million (+65.5% year on year).
Year-on-year revenue growth: 12 months in a row. →
In Oct 2026, it ranked No. 112 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$35.8 million | +8.7% | -53.7% |
| Sep 2026 | NT$77.2 million | +73.7% | +26.7% |
| Aug 2026 | NT$60.9 million | +64.0% | +32.6% |
| Jul 2026 | NT$46 million | +10.7% | -48.3% |
| Jun 2026 | NT$88.9 million | +83.5% | +47.4% |
| May 2026 | NT$60.3 million | +134.9% | -1.1% |
| Apr 2026 | NT$61 million | +41.8% | -7.6% |
| Mar 2026 | NT$66 million | +72.5% | -8.2% |
| Feb 2026 | NT$71.9 million | +81.3% | -9.0% |
| Jan 2026 | NT$79 million | +87.9% | +44.9% |
| Dec 2025 | NT$54.5 million | +134.7% | +87.0% |
| Nov 2025 | NT$29.2 million | +58.8% | -11.4% |
| Oct 2025 | NT$32.9 million | -23.7% | -25.9% |
| Sep 2025 | NT$44.5 million | +139.6% | +19.7% |
| Aug 2025 | NT$37.2 million | +125.4% | -10.5% |
| Jul 2025 | NT$41.5 million | +4.0% | -14.3% |
| Jun 2025 | NT$48.4 million | +32.2% | +88.7% |
| May 2025 | NT$25.7 million | -17.3% | -40.3% |
| Apr 2025 | NT$43 million | +25.7% | +12.4% |
| Mar 2025 | NT$38.3 million | +98.7% | -3.5% |
| Feb 2025 | NT$39.7 million | +75.3% | -5.7% |
| Jan 2025 | NT$42.1 million | +6.5% | +80.9% |
| Dec 2024 | NT$23.2 million | -36.7% | +26.5% |
| Nov 2024 | NT$18.4 million | -76.1% | -57.4% |
| Oct 2024 | NT$43.2 million | +186.8% | +132.5% |
Jan–Oct 2026 cumulative: NT$648 million (+65.5% YoY)
Other Biotech & Medical companies
Compare with peers: Applied BioCode vs PEC / Applied BioCode vs Lotus Pharm / Applied BioCode vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本年度累積營收增長,主係市場開發成果與客戶需求提升,致使出貨增加。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16